Related Experiment Video
Updated: Dec 13, 2025

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina
Published on: June 23, 2014
Inactivation of Endothelial ADAM17 Reduces Retinal Ischemia-Reperfusion Induced Neuronal and Vascular Damage
Diana R Gutsaeva1, Lamiaa Shalaby1, Folami L Powell2
1Department of Ophthalmology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Abstract:
Retinal ischemia contributes to visual impairment in ischemic retinopathies. A disintegrin and metalloproteinase ADAM17 is implicated in multiple vascular pathologies through its ability to regulate inflammatory signaling via ectodomain shedding. We investigated the role of endothelial ADAM17 in neuronal and vascular degeneration associated with retinal ischemia reperfusion (IR) injury using mice with conditional inactivation of ADAM17 in vascular endothelium. ADAM17Cre-flox and control ADAM17flox mice were subjected to 40 min of pressure-induced retinal ischemia, with the contralateral eye serving as control. Albumin extravasation and retinal leukostasis were evaluated 48 h after reperfusion. Retinal morphometric analysis was conducted 7 days after reperfusion. Degenerate capillaries were assessed by elastase digest and visual function was evaluated by optokinetic test 14 and 7 days following ischemia, respectively. Lack of ADAM17 decreased vascular leakage and reduced retinal thinning and ganglion cell loss in ADAM17Cre-flox mice. Further, ADAM17Cre-flox mice exhibited a remarkable reduction in capillary degeneration following IR. Decrease in neurovascular degeneration in ADAM17Cre-flox mice correlated with decreased activation of caspase-3 and was associated with reduction in oxidative stress and retinal leukostasis. In addition, knockdown of ADAM17 resulted in decreased cleavage of p75NTR, the process known to be associated with retinal cell apoptosis. A decline in visual acuity evidenced by decrease in spatial frequency threshold observed in ADAM17flox mice was partially restored in ADAM17-endothelial deficient mice. The obtained results provide evidence that endothelial ADAM17 is an important contributor to IR-induced neurovascular damage in the retina and suggest that interventions directed at regulating ADAM17 activity can be beneficial for alleviating the consequences of retinal ischemia.
Insights
Endothelial ADAM17 (a disintegrin and metalloproteinase) exacerbates retinal ischemia reperfusion injury by increasing vascular leakage and neurovascular damage. Inhibiting ADAM17 in endothelial cells offers a potential therapeutic strategy for vision impairment.
Area of Science:
- Vascular Biology
- Neuroscience
- Ophthalmology
Background:
- Retinal ischemia causes vision loss in ischemic retinopathies.
- ADAM17 (a disintegrin and metalloproteinase) is involved in vascular pathologies by regulating inflammatory signaling.
- Endothelial ADAM17's role in retinal ischemia reperfusion (IR) injury is not fully understood.
Purpose of the Study:
- To investigate the role of endothelial ADAM17 in neurovascular and vascular degeneration following retinal IR injury.
- To assess the therapeutic potential of targeting endothelial ADAM17.
Main Methods:
- Used mice with conditional inactivation of ADAM17 in vascular endothelium (ADAM17Cre-flox) and controls (ADAM17flox).
- Induced retinal IR injury and evaluated vascular leakage, leukostasis, capillary degeneration, ganglion cell loss, and visual function.
- Assessed caspase-3 activation, oxidative stress, and p75NTR cleavage.
Main Results:
- Lack of endothelial ADAM17 reduced vascular leakage, retinal thinning, ganglion cell loss, and capillary degeneration post-IR.
- Neurovascular protection correlated with decreased caspase-3 activation, oxidative stress, and leukostasis.
- ADAM17 deficiency partially restored visual acuity and decreased p75NTR cleavage.
Conclusions:
- Endothelial ADAM17 significantly contributes to IR-induced neurovascular damage in the retina.
- Targeting endothelial ADAM17 may be a promising therapeutic approach for retinal ischemia consequences.

